Logo

NKLR

Terra Innovatum Global N.V. Ordinary shares

NKLR

Terra Innovatum Global N.V. Ordinary shares NASDAQ
$4.66 7.37% (+0.32)

Market Cap $323.34 M
52w High $21.91
52w Low $3.73
Dividend Yield 0%
P/E -51.78
Volume 219.18K
Outstanding Shares 69.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.29K $-2.987K 0% $-0.043 $0
Q2-2025 $0 $535.072K $1.903M 0% $0.065 $1.903M
Q1-2025 $0 $1.26M $1.163M 0% $0.04 $1.163M
Q4-2024 $0 $346.579K $1.066M 0% $0.036 $1.066M
Q3-2024 $0 $85.81K $-85.81K 0% $-0.003 $-85.81K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.151M $3.748M $7.978M $-4.23M
Q2-2025 $862.127K $237.235M $10.071M $227.164M
Q1-2025 $1.328M $235.287M $10.025M $225.261M
Q4-2024 $1.787M $233.348M $9.25M $224.098M
Q1-2024 $1.677K $0 $4 $-4

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.987K $-2.763M $-94K $5.759M $1.289M $-2.41K
Q2-2025 $-1.296K $-685 $0 $2.491K $0 $-685
Q1-2025 $-1.296K $-685 $0 $2.491K $0 $-685
Q4-2024 $1.066M $-553.615K $-230M $232.341M $1.787M $-553.62K
Q3-2024 $16 $9.653 $0 $0 $10.046 $9.653

Five-Year Company Overview

Income Statement

Income Statement Terra Innovatum looks like a very early-stage, pre-revenue business. The data shown as zeroes almost certainly means detailed financials are not yet reported in this feed, not that the company has no expenses. In practical terms, this is likely a company burning cash on engineering, regulatory work, and corporate overhead with no meaningful revenue yet. Until the first reactors are deployed and long-term supply or service contracts start generating income, the income statement will probably show continuing net losses typical of a development-stage energy technology company.


Balance Sheet

Balance Sheet The balance sheet information is effectively blank here, so it’s hard to judge financial strength from this data alone. Given the recent listing via a SPAC, the company likely holds some cash from the transaction but also faces substantial future funding needs to build factories, complete prototypes, and navigate licensing. Capital intensity in nuclear is high, so future balance-sheet health will depend heavily on access to additional equity or debt, the structure of partnerships, and how carefully management controls spending before commercial revenue appears.


Cash Flow

Cash Flow Reported cash-flow figures are also effectively unavailable, but the business model and stage imply negative operating cash flow as the company spends on R&D, licensing, and early commercialization efforts. Free cash flow is almost certainly negative and may remain that way for several years until the first commercial units are deployed and paid for. The key cash-flow questions going forward will be: how fast spending ramps, how lumpy project cash inflows are, and whether partnerships and customer prepayments can offset some of the burn.


Competitive Edge

Competitive Edge Competitively, Terra Innovatum is trying to carve out a niche in micro‑modular nuclear reactors with a design that emphasizes standard fuel, off‑the‑shelf components, inherent safety, and compact, modular deployment. Using widely available low‑enriched uranium and factory-built modules aims to avoid some of the supply and cost issues that challenge other advanced reactor concepts. Early regulatory engagement and partnerships in manufacturing, energy services, and defense are positives. The risks lie in intense competition from other advanced nuclear and clean‑energy technologies, long and uncertain regulatory timelines, and the challenge of proving real‑world reliability and cost at scale before rivals or alternatives gain the upper hand.


Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the story. The SOLO™ reactor design targets small, modular units that can be built in factories, run autonomously, and serve diverse uses—from powering data centers and remote facilities to producing medical isotopes and industrial heat. The focus on inherent safety, compact footprint, and a flexible fuel path is a meaningful differentiator on paper. The big execution tests will be demonstrating that the technology works as promised, keeping timelines for the first deployments realistic, scaling manufacturing without quality issues, and converting early letters of intent and MOUs into binding, revenue‑generating contracts.


Summary

Overall, Terra Innovatum is best viewed as an early-stage, high-uncertainty nuclear technology platform rather than a mature utility-like energy company. The financial profile today is characterized by no operating revenue and likely substantial development spending, so the main factors to watch are technology milestones, regulatory progress, strength and depth of partnerships, and evidence of real customer demand. If the company can meet its ambitious deployment schedule and scale production, it could secure a differentiated position in micro‑modular nuclear. If delays, cost overruns, or regulatory setbacks occur—as is common in nuclear—timelines and funding needs could stretch materially. This is a story driven far more by execution and technology risk than by current financial metrics.